Best Trucking Companies To Own For 2015

The first quarter of 2014 is coming to a close, and it was a slow one for MLP IPOs. The only MLP that debuted in the last three months was�Cypress Energy Partners�(NYSE: CELP), but there are several others in the pipeline. Here is how the IPO landscape looks as we end Q1.

Cypress debuted on Jan. 14 as the first MLP IPO of 2014. It sold 3,750,000 units at $20 per unit. CELP is a growth-oriented MLP providing saltwater disposal and other water and environmental services to US onshore oil and natural gas producers and trucking companies in North Dakota and west Texas. The partnership agreement calls for a minimum quarterly distribution of $0.3875 per unit for each whole quarter, or $1.55 per unit on an annualized basis. At Friday�� closing price of $21.87, that translates into an annualized yield of 7.1 percent.

The next IPO may be Enable Midstream Partners, which was formed in May 2013 as a joint venture by affiliates of CenterPoint Energy, OGE Energy and ArcLight Capital Partners. Enable Midstream Partners filed its S-1 with the Securities and Exchange Commission (SEC) back in November, and the offering had been expected in the first quarter of 2014. An�amended registration form�was filed on Friday.

Best Trucking Companies To Own For 2015: UBS AG (UBSN.VX)

UBS AG, incorporated on February 28, 1978, is a client-focused financial services company that offers a combination of wealth management, asset management and investment banking services on a global and regional basis. UBS AG is the parent company of the UBS Group (Group).The operational structure of the Company consists of the Corporate Center and four business divisions: Wealth Management & Swiss Bank, Wealth Management Americas, Global Asset Management and the Investment Bank. As of December 31, 2011, the Company operated about 877 business and banking locations worldwide, of which about 42% were in Switzerland, 42% in the Americas, 11% in the rest of Europe, Middle East and Africa, and 5% in Asia-Pacific. During the year ended December 31, 2011, it completed acquisitions in Global Asset Management and in the equities business of the Investment Bank. In November 2011, investment management responsibility for a private equity fund of funds was transferred to Global Asset Management from Wealth Management & Swiss Bank. In October 2011, Global Asset Management acquired ING Investment Management Limited business in Australia. In July 2011, the infrastructure and private equity fund of funds businesses were transferred from its alternative and quantitative investment area to its infrastructure investment area. In January 2011, investment management responsibility for a multi-manager alternative fund was transferred to Global Asset Management from Wealth Management & Swiss Bank.

Wealth Management

Wealth Management provides wealthy private clients with financial advice, products and tools to fit their individual needs. As of December 31, 2011, Wealth Management had presence in over 40 countries and approximately 200 wealth management and representative offices, half of which are outside Switzerland, mostly in Europe, Asia Pacific, Latin America and the Middle East. During 2011, the Company had CHF 750 billion of invested assets. The Company offers products and services to private! clients, focusing in particular on the ultra-high-net-worth (clients with investable assets of more than CHF 50 million) and high-net-worth client segments (clients with investable assets between CHF 2 million and CHF 50 million). In addition, it also provides wealth management solutions, products and services to financial intermediaries. Wealth Management has a presence in over 40 countries and approximately 200 wealth management and representative offices, half of which are outside Switzerland, mostly in Europe, Asia Pacific, Latin America and the Middle East.

The Company�� Global Financial Intermediaries (Global FIM) business serves approximately 1,700 asset managers. It provides its clients with the financial advice, products and tools. The Company�� clients can trade a range of financial instruments from single securities, such as equities and bonds, to various investment funds, structured products and alternative investments. Additionally, it offers structured lending, corporate finance and wealth planning advice on client needs, such as funding for education, inheritance and succession. For its ultra high net worth clients, it offers institutional-like servicing that provides access to its Investment Bank and Global Asset Management offerings. Wealth Management also gives clients access to the knowledge, and product and service offerings from Global Asset Management and the Investment Bank, complemented by an open product platform providing access to an array of products from third-party providers.

The Company competes with Credit Suisse, Julius Bar, HSBC, Deutsche Bank, JP Morgan, Citigroup, Barclays and Unicredit.

Retail & Corporate

The Company delivers financial products and services to its retail, corporate and institutional clients. The Retail & Corporate unit is a core element of UBS Switzerland�� universal bank delivery model. As of December 31, 2011, the Company had a network of around 300 branches, 1,250 automated teller machines! , self-se! rvice terminals and customer service centers, alongside e-banking and mobile banking. The Company�� retail clients have access to offering, including cash accounts, payments, savings and retirement solutions, investment fund products, residential mortgages, as well as life insurance and advisory services. It provides financing solutions to its corporate clients, offering access to capital markets (equity and debt capital), syndicated and structured credit, private placements, leasing and traditional financing. The Company�� transaction banking offers solutions for payments and cash management services, trade and export finance, receivable finance, as well as global custody solutions to institutional clients.

The Company competes with Credit Suisse, Raiffeisen and PostFinance.

Wealth Management Americas

Wealth Management Americas provides advice-based relationships through its financial advisors, who deliver a range of wealth management solutions. On December 31, 2011, the business division had CHF 709 billion in invested assets. Wealth Management Americas consisted of branch networks in the United States, Puerto Rico and Canada, with 6,967 financial advisors as of 31 December 2011. Most corporate and operational functions of the business division are located in the home office in Weehawken, New Jersey. In the United States and Puerto Rico, Wealth Management Americas operates through direct and indirect subsidiaries of UBS AG. Securities and operations activities are conducted primarily through two broker-dealers, UBS Financial Services Inc. and UBS Financial Services Incorporated of Puerto Rico. Its banking services in the United States include those conducted through the UBS AG branches and UBS Bank USA, a federally regulated Utah bank, which provides Federal Deposit Insurance Corporation (FDIC) insured deposit accounts. It includes the domestic US business, the domestic Canadian business and international business booked in the United States.

Ca! nadian we! alth management and banking operations are conducted through UBS Bank (Canada). The Company�� include wealth accumulation and preservation, income generation and portfolio diversification. The Company�� advisors work closely with internal consultants in areas, such as wealth planning, portfolio strategy, retirement and annuities, alternative investments, managed structured products, banking and lending, equities, and fixed income accounts, structured products, banking and lending, equities, and fixed income retirement and annuities, alternative investments, managed accounts, structured products, banking and lending, equities, and fixed income. It also offers lending and cash management services, such as securities-backed lending, the resource management account, FDIC-insured deposits, mortgages and credit cards. For corporate and institutional clients, it offers a range of solutions, including equity compensation, administration, investment consulting, defined benefit and contribution programs and cash management services. It offers a range of equity and fixed income instruments.

The Company competes with Bank of America, Morgan Stanley and Wells Fargo.

Global Asset Management

The Company serves third-party institutional and wholesale clients and the clients of UBS�� wealth management businesses. The Company�� fund services unit, a global fund administration business, provides professional services, including legal fund set-up, accounting and reporting. Invested assets totaled CHF 574 billion and assets under administration were CHF 375 billion on December 31, 2011. Global Asset Management serves third-party institutional and wholesale clients, and the clients of UBS�� wealth management businesses. Global Asset Management�� business lines include traditional investments (equities, fixed income and global investment solutions); alternative and quantitative investments; global real estate; infrastructure and private equity, and fund services.

Global ! investment solutions offer asset allocation, currency, multi-manager, structured solutions, risk advisory and strategic investment advisory services. Alternative and quantitative investments has two primary business lines-Alternative Investment Solutions (AIS) and O��onnor. AIS offers a range of hedge fund solutions and advisory services, including multi-manager strategies. O��onnor is a provider of single-manager global hedge funds. Global real estate manages real estate investments globally and regionally within Asia, Europe, Switzerland and the United States. Infrastructure and private equity manages direct infrastructure investment and multi-manager infrastructure and private equity strategies for both institutional and high net worth investors. Infrastructure asset management manages direct investments in core infrastructure assets worldwide. Fund services, the global fund administration business, provides professional services, including legal set-up, reporting and accounting for retail and institutional investment funds, hedge funds and other alternative products.

The Company competes with Fidelity Investments, AllianceBernstein Investments, BlackRock, JP Morgan Asset Management and Goldman Sachs Asset Management.

Investment Bank

The Investment Bank provides a range of products and services in equities, fixed income, foreign exchange and commodities to corporate and institutional clients, sovereign and government bodies, financial intermediaries, alternative asset managers and UBS�� wealth management clients. The Investment Bank has three business areas: equities, fixed income, currencies and commodities (FICC), and the investment banking department. The Company operates through branches and subsidiaries of UBS AG. Securities activities in the United States are conducted through UBS Securities LLC, a broker-dealer. Securities research provides investment analysis across a range of asset classes of more than 3,400 companies worldwide.

The ! Company p! articipates in the primary and secondary markets for cash equity and equity-related products, including listed options, structured products, equity-linked securities, swaps, futures and over-the-counter (OTC) derivative contracts. Cash equities provide clients with liquidity, investment advisory, trade execution and related consultancy services. It offers trade execution for single stocks and portfolios, including capital commitment, block trading, small-cap execution and commission management services. In addition, it also provides clients with a range of electronic trading algorithms and analytical tools. Derivatives and equity-linked provides a range of flow, structured, synthetic and equity-linked products with worldwide access to primary and secondary markets.

Prime services offer brokerage business, including clearing and custody, capital consultancy, financing, securities lending and equity swaps execution. The FICC business area delivers products and solutions to corporate, institutional and public-sector clients in all markets, as well as to private clients via targeted intermediaries. Macro consists of the foreign exchange, money market and interest rate sales and trading businesses, as well as cash and collateral trading. It provides a range of foreign exchange, precious metals, treasury, and liquidity management solutions to institutional and private clients via targeted intermediaries. Credit sales and trading consists of the origination, underwriting, trading and distribution of cash and synthetic products across the credit spectrum - bonds, derivatives, notes and loans.

The investment banking department provides advice and a range of capital markets execution services to corporate clients, financial institutions, financial sponsors, sovereign clients and hedge funds. The Company also provides liquidity in local markets across foreign exchange, credit, rates and structured products. The advisory group assists in acquisitions and sale processes, and also advises on! reviews ! and corporate restructuring solutions. Global capital markets is a joint venture with the securities business. It offers financing and advisory services that cover all forms of capital raising, as well as risk management solutions. Global leveraged finance provides event-driven (acquisition, leveraged buyout) loans, and bond and mezzanine leveraged finance to corporate clients and financial sponsors.

The Company competes with Bank of America/Merrill Lynch, Barclays Capital, Citigroup, Credit Suisse, Deutsche Bank, Goldman Sachs, JP Morgan Chase and Morgan Stanley.

Advisors' Opinion:

• [By Telis Demos]

  UBS AG(UBSN.VX) has named a new head of its U.S. group that works on complex stock financings and investments for companies and wealthy individuals.

• [By Paul Vigna]

  After rising as high as 1897 intraday, the S&P 500 took a straight dive down, and is now bouncing and churning around this key support level. The index tested it briefly at the open, falling to 1841.95, bounced off it again, then came back to it again. The day’s low, so far, is 1839.92. UBS's(UBSN.VX) Art Cashin puts the critical range between 1837-1840. John O’Hara at FBN thinks the market is going to churn in the 1820-1840 area this week, and test that lower boundary. “That would be a good set-up for a rally into week’s end,” he wrote.

Best Trucking Companies To Own For 2015: Molex Incorporated(MOLX)

Molex Incorporated, together with its subsidiaries, engages in the design, manufacture, and sale of electronic components worldwide. It offers micro-miniature connectors, B-to-B connectors, SIM and SD card sockets, keypads, electromechanical subassemblies, internal and on-ground antennas, standard antennas, magnetic jacks, and subsystems for the telecommunications market; and power, optical, and signal connectors and cables for end-to-end data transfer, linking disk drives, controllers, servers, switches, and storage enclosures for the info-tech market. The company also designs and manufactures connectors for home and portable audio, digital still and video cameras, DVD players, and recorders, as well as devices that combine multiple functions in the consumer market, earphones, jumpers, and components for gaming machines. In addition, it provides network interface cards, software for industrial networks, cord sets, electrical solutions, and I/O connectors for industrial pr oduction equipment, as well as portable lighting to power distribution solutions for commercial construction, utility, petrochemical, and food and beverage industries; and cable assemblies, sealed and panel mount connectors, and other products for use in the infotainment and navigation, powertrain, safety and chassis, and body electronics in the automotive market. Further, the company offers connectors and custom integrated systems for diagnostic and therapeutic equipment used in hospitals, including x-ray, magnetic resonance imaging, and dialysis machines; and solid-state lighting products. Additionally, it provides manufacturing services to integrate specific components into a customer?s product. The company sells its products directly to original equipment manufacturers, contract manufacturers, and distributors. It markets its products through direct sales force and a network of distributors. Molex Incorporated was founded in 1938 and is based in Lisle, Illinois.

Advisors' Opinion:

• [By Chris Hill]

  Molex (NASDAQ: MOLX  ) is up big after Koch Industries agreed to buy the company for $7.2 billion in cash. Yum! Brands' (NYSE: YUM  ) same-store sales in China fall 10% in August. Caterpillar (NYSE: CAT  ) shares are up on news that China's exports grew more than 7% in August. And Middleby (NASDAQ: MIDD  ) closes in on a new all-time high. In this segment, the guys discuss four stocks making big moves.

• [By Diane Alter]

  Koch Industries, one of the largest private companies in the United States, announced Monday it will buy electronic components manufacturer Molex Inc. (Nasdaq: MOLX) for $7.2 billion.

• [By Paul Ausick]

  Stocks on the move: Delta Air Lines Inc. (NYSE: DAL) is up 9.3% at $21.74 after being adding to the S&P 500 index. BlackBerry Ltd. (NASDAQ: BBRY) is up 6.4% at $11.53 on reports that a former board member has nearly lined up financing to take the company private. Molex Inc. (NASDAQ: MOLX) is up 31.6% at $38.60 following an agreement to be acquired by Koch Industries Inc.

• [By Alexis Xydias]

  Molex (MOLX) soared 32 percent to $38.63 for the largest increase in the S&P 500. The maker of electronic components for products such as Apple�� iPhone agreed to a $7.2 billion acquisition by Koch Industries, the holding company controlled by the billionaire Koch brothers.

Top 5 Consumer Companies To Watch For 2015: Credicorp Ltd (BAP)

Credicorp Ltd. (Credicorp), incorporated on October 20, 1995, is a financial services holding company. The Company is organized in four operating segments: Banking, Insurance, Pension funds and Brokerage and other. Credicorp is engaged principally in banking (including commercial and investment banking), insurance (including commercial property, transportation and marine hull, automobile, life, health and underwriting insurance), pension funds (including private pension fund management services), and brokerage and other (including the structuring and placement of primary market securities issues and the execution and trading of secondary market transactions.). Its four operating subsidiaries are : Banco de Credito del Peru (BCP), Atlantic Security Bank (ASB), El Pacifico-Peruano Suiza Compania de Seguros y Reaseguros, and Prima AFP.

Banking segment

Banking includes handling loans, credit facilities, deposits and current accounts, and providing investment banking services, including corporate finance, both for corporate and institutional customers. Banking also includes handling deposits consumer loans and credit cards facilities for individual customers. The Company conducts banking activities in Bolivia through BCP Bolivia, a service commercial bank. Its banking business is organized into wholesale banking activities, which are carried out by BCP�� wholesale banking group (which includes the corporate banking operations of ASB), and retail banking activities, which are carried out by BCP's retail banking group. Its deposit-taking operations are managed by BCP'�� retail banking group and and ASB's private banking group.

Insurance

Credicorp�� insurance segment includes commercial property, transportation and marine hull, automobile, life, health and pension fund underwriting insurance. Private hospital services are also included under this operating segment. The Company conducts its insurance operations Grupo Pacifico and its subsidiaries, whic! h provide a broad range of insurance products. Grupo Pacifico property and casualty insurance through Pacifico Seguros, life and pension insurance through Pacifico Vida, and health care insurance through Pacificosalud EPS.. Grupo Pacifico sells its products both directly and through independent brokers and agents.

Pension funds

Credicorp�� pension funds segment provides private pension fund management services to customers. Credicorp conducts all of its pension fund activities through its private pension fund administrator Prima AFP. Credicorp through its subsidiary Prima AFP, focuses mainly on obtaining new affiliates, by providing permanent information and diverse channels of communication.

Brokerage and other

The Company�� brokerage and others segment includes the structuring and placement of primary market issues and the execution and trading of secondary market transactions. This segment also includes offers of local securitization structuring to corporate entities, management of mutual funds and other services. The majority of its trading and brokerage activities are conducted through BCP, ASB and Credicorp Securities Inc. Its asset management business is carried out by BCP in Peru, through its subsidiary Credifondo, and by ASB. It offers Brokerage and other services through BCP and ASB. BCP offers clients a range of such products and services, such as brokerage, mutual funds and custody services through its branch network in Lima and throughout the rest of Peru. In addition, ASB also offers brokerage and other services.

The Company competes with BCP, BBVA Banco Continental, Scotiabank Peru, Interbank and Banco Interamericano de Finanzas.

Advisors' Opinion:

• [By Chuck Carnevale]

  Credit Corp. Limited (BAP)

  My first featured aggressive financial candidate is Credit Corp. Limited, a Bermuda-based financial services holding company, and the largest financial holding company in Peru. Although the company is headquartered in Bermuda and operates in Peru, its long-term track record is exceptional. Once again, I will let the F.A.S.T. Graphs��speak for themselves, other than to say in addition to a great track record, this ADR is expected to offer above-average growth and appears to be very attractively valued at today�� levels.

Best Trucking Companies To Own For 2015: POWERSHARES DYNAMIC BLDG & CONSTR PORT (PKB)

PowerShares Dynamic Building & Construction Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dynamic Building & Construction Intellidex Index (the Building & Construction Intellidex). The Building & Construction Intellidex consists of stocks of 30 United States building and construction companies. These are companies that are primarily engaged in providing construction and related engineering services for building and remodeling residential properties, commercial or industrial buildings, or working on large-scale infrastructure projects, such as highways, tunnels, bridges, dams, power lines and airports. These companies may also include manufacturers of building materials for home improvement and general construction projects, and specialized machinery used for building and construction; companies that provide installation/maintenance/repair work, and land developers. Stocks are selected principally on the basis of their capital appreciation potential as identified by the AMEX (the Intellidex Provider) pursuant to an Intellidex methodology. The Fund�� investment advisor is PowerShares Capital Management LLC.

The Fund, using an indexing investment approach, attempts to replicate the performance of the Building & Construction Intellidex. The Fund generally will invest in all of the stocks comprising the Building & Construction Intellidex in proportion to their weightings in the Building & Construction Intellidex. The Fund will normally invest at least 80% of its total assets in common stocks of building and construction companies. It will normally invest at least 90% of its total assets in common stocks that comprise the Building & Construction Intellidex.

Advisors' Opinion:

• [By John Udovich]

  Small cap building materials stock NCI Building Systems Inc (NYSE: NCS) fell yesterday after announcing a share offering plus its investors have (so-far) missed out on any ��ecovery��in construction���meaning it might be time to take a closer look at the stock along with potential performance benchmarks like the PowerShares Dynamic Building & Construction ETF (NYSEARCA: PKB) and the First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM)���both of which have had decent returns in recent years.

Best Trucking Companies To Own For 2015: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Keith Speights]

  Sarepta Therapeutics (NASDAQ: SRPT  ) announced yesterday after the market closed that the U.S. Food and Drug Administration requested additional information before it could make a decision on acceptability of an accelerated approval filing for its Duchenne muscular dystrophy drug eteplirsen. Sarepta shares were down more than 12% in early trading.